Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
JAK2 activation by growth hormone and other cytokines
At the end of 2016, the Amgen team filed a patent (US20170275370A1) titled "Methods for Treating or Ameliorating Metabolic Disorders Using a GIPR Binding Protein in Combination with a GLP-1 Agonist." This reported the therapeutic potential of using an antibody targeting the GIPR in combination with a GLP-1 receptor agonist for the treatment of type 2 diabetes, obesity, dyslipidemia, elevated levels of glucose, increased insulin levels, and diabetic nephropathy
The three mouse models were SAMP-1 female mice with accelerated aging, wild rats, SAMR-1, and SHR (both female mice)
The animals were fed a normal-fat diet (ND, 10% fat calories) or HFD (60% fat calories) (Research Diets Inc., New Brunswick, NJ, USA) ad libitum for 8 weeks
US$ 21.23
US$ 27.32
US$ 20.02
US$ 25.42
US$ 29.60
US$ 26.28
US$ 24.04
